COMP <GO>
VKTX vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Viking Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: VKTX 3
— ABBV 7
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: VKTX
LAST: $26.86 (+5.92%) • MKT CAP: $3.38B
balance-sheet
24.02
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VKTX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VKTX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.25% | 3.47% | -11.72 | ABBV | /fcf-yield <GO> |
| Operating Margin | — | 24.60% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 6.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 15.40% | 8.60% | +6.80 | VKTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 24.02 | 5.33 | +18.69 | VKTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.5 | 65.1 | -18.60 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.15 | -0.24 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 113.1x | -78.10 | VKTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.38B | $513.86B | -$510.48B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VKTX REV | ABBV REV | VKTX GROSS % | ABBV GROSS % | VKTX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$278.7M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$87.8M | $17.83B |
| FY 2023 | $0 | $54.32B | — | — | -$73.4M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VKTX // BETA 0.91
ABBV // BETA 1.15